| Trial Identifier: | D361FC00001 |
| Sponsor: | AstraZeneca |
| Collaborator: |
Parexel
|
| NCTID:: | NCT05008055 |
| Start Date: | November 2021 |
| Primary Completion Date: | August 2023 |
| Study Completion Date: | June 2024 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| Spanish (Spain) Translation | |
| Spanish (US) Translation | |
| French (Canada) Translation | |
| French (France) Translation | |
| Korean (South Korea) Translation |
| Country | Location |
|---|---|
| CA, BC | Victoria, BC, CA, V8R 6V5 |
| DK | Aarhus N, DK, DK8200 |
| ES | Badalona, ES, 08003 |
| ES | Barcelona, ES, 8035 |
| ES | Madrid, ES, 28040 |
| ES | Madrid, ES, 28046 |
| FR | POITIERS, FR, 86021 |
| FR | Villejuif Cedex, FR, 94805 |
| GB | Cambridge, GB, CB2 0QQ |
| GB | Manchester, GB, M20 4BX |
| GB | Sutton, GB, SM2 5PT |
| KR | Busan, KR, 49241 |
| KR | Seoul, KR, 3722 |
| KR | Seoul, KR, 06351 |
| US, CA | Duarte, CA, US, 91010 |
| US, CA | Los Angeles, CA, US, 90095 |
| US, TX | Houston, TX, US, 77030 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company